Asset Details
Do you wish to reserve the book?
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
Do you wish to request the book?
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
2020
Overview
ObjectiveProgrammed death ligand 1 (PD-L1) expression affects tumor evasion of immune surveillance. The prognostic value and relationship of PD-L1 expression to T-cell–inflamed immune signatures in ovarian cancer are unclear. The purpose of this study is to evaluate the impact of PD-L1 on overall survival and its correlation with an immune-mediated gene expression profile in patients with advanced ovarian cancer.MethodsPD-L1 expression in tumor and immune cells was assessed by immunohistochemistry, and PD-L1–positive expression was defined as a combined positive score ≥1; a T-cell–inflamed gene expression profile containing interferon γ response genes was evaluated using extracted RNA from surgical samples. Associations between PD-L1 expression, gene expression profile status, and overall survival were analyzed using the Kaplan-Meier method, log-rank test, and multivariate Cox proportional hazards regression models.ResultsA total of 376 patients with advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer treated by cytoreductive surgery and platinum-based therapy were included. PD-L1–positive expression was observed in 50.5% of patients and associated with more advanced stage (p=0.047), more aggressive histologic subtype (p=0.001), and platinum sensitivity defined by increasing treatment-free interval from first platinum-based chemotherapy to next systemic treatment (p=0.027). PD-L1–positive expression was associated with longer overall survival in multivariate analyses (adjusted HR 0.72, 95% CI 0.56 to 0.93). In subgroup analyses, this association was most pronounced in patients with partially platinum-sensitive disease (treatment-free interval ≥6 to <12 months). T-cell–inflamed gene expression profile status correlated with PD-L1 expression (Spearman, ρ=0.712) but was not an independent predictor of overall survival.ConclusionPD-L1 expression is associated with longer overall survival among advanced ovarian cancer patients. PD-L1 expression may be an independent prognostic biomarker.
Publisher
Elsevier Inc,by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology,Elsevier Limited
Subject
/ Aged
/ B7-H1 Antigen - biosynthesis
/ Carcinoma, Ovarian Epithelial - genetics
/ Carcinoma, Ovarian Epithelial - immunology
/ Carcinoma, Ovarian Epithelial - mortality
/ Cytoreduction Surgical Procedures
/ Female
/ Gene Expression - immunology
/ Humans
/ Ligands
/ Organoplatinum Compounds - administration & dosage
/ Ovarian Neoplasms - genetics
/ Ovarian Neoplasms - immunology
/ Ovarian Neoplasms - mortality
/ Patients
/ Surgery
/ Tumors
